These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25222410)

  • 1. Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding.
    Winkelmayer WC
    Ann Intern Med; 2014 Sep; 161(6):JC10. PubMed ID: 25222410
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Review: In AF or VTE, direct oral anticoagulants reduce fatal bleeding compared with vitamin K antagonists.
    Lazo-Langner A
    Ann Intern Med; 2015 Oct; 163(8):JC2. PubMed ID: 26502139
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].
    Korin J
    Medicina (B Aires); 2012; 72(5):419-24. PubMed ID: 23089119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral anticoagulants. Large study finds minor risk of hemorrhage in the elderly].
    MMW Fortschr Med; 2011 Sep; 153(37):16. PubMed ID: 21950182
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin K antagonists: beyond bleeding.
    Krüger T; Floege J
    Semin Dial; 2014; 27(1):37-41. PubMed ID: 24400802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
    Proietti M; Lip GY
    Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
    Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
    Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
    Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
    Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction and treatment of bleeding in patients under anticoagulant treatment.
    Páramo JA
    Med Clin (Barc); 2021 Jan; 156(1):20-25. PubMed ID: 33218693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis.
    Renda G; Ricci F; De Caterina R
    Am J Med; 2017 Apr; 130(4):457-461. PubMed ID: 27751896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
    Harel Z; Sood MM; Perl J
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):183-92. PubMed ID: 25636144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of direct oral anticoagulants in chronic kidney disease.
    Parker K; Thachil J
    Br J Haematol; 2018 Oct; 183(2):170-184. PubMed ID: 30183070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consistency of safety profile of new oral anticoagulants in patients with renal failure.
    Lega JC; Bertoletti L; Gremillet C; Boissier C; Mismetti P; Laporte S
    J Thromb Haemost; 2014; 12(3):337-43. PubMed ID: 24350682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Direct Oral Anticoagulants in Special Populations.
    Li A; Lopes RD; Garcia DA
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1053-71. PubMed ID: 27637307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.